公司简介
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi...
关联新闻
- Weight-loss drugs' hit to UK grocery spending tops £1 billion, Worldpanel says
The impact of weight-loss drugs on UK grocery spending has surpassed £1 billion ($1.32 billion), as new pill formats and rising uptake among men accelerate their use, researcher Worldpanel by Numera...
- Eli Lilly to Buy Calytrix Bio for Up to $1.5 Billion
Calytrix Bio, a privately held biotechnology company backed by JPMorgan Chase, is developing therapies aimed at a group of rare blood cancers.
- Lilly to buy Calytrix Bio for up to $1.5 billion
Eli Lilly has agreed to acquire Calytrix Bio for up to $1.5 billion in cash to expand the development of treatments for rare blood cancers, the privately held biotech said on Monday.
- Mapping the Market: Eli Lilly shares ready to rally again
Shares in Eli Lilly rose more than 70% from their 2026 low to the record high they hit on Thursday, and more gains could be in store, technical analysis indicates.
- The world's most sophisticated drug companies are putting billions into vaccines — despite the political environment
Look at the promising data for Moderna and Merck's experimental cancer vaccine and the research suggesting the shingles vaccine can delay dementia.
- China approves Eli Lilly's weight loss pill orforglipron
China approves Eli Lilly's weight loss pill orforglipron
- FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound
The FDA is requiring the makers of all GLP-1 medications to add a warning about the potential increased risk of NAION. NAION is a rare condition caused by decreased blood flow to the front part of the...
- U.S. regulators are requiring the makers of blockbuster drugs like Ozempic and Zepbound to include warnings about a rare eye condition that can cause permanent vision loss
The FDA is requiring the makers of drugs like Ozempic and Zepbound to include warnings about a rare eye condition that can cause permanent vision loss.